Showing 5701-5710 of 8728 results for "".
- DREAM Initiative from Allergan Aesthetics, SkinBetter Science Launches CARE Curriculumhttps://practicaldermatology.com/news/dream-initiative-from-allergan-skinbetter-science-launches-care-curriculum/2461334/The DREAM Initiative®, developed by Allergan Aesthetics and skinbetter science®, has supported the development of a racial equity curriculum for dermatology residency programs. The Curriculum f
- Daxxify from Revance Gets FDA Greenlighthttps://practicaldermatology.com/news/daxxify-from-revance-gets-fda-greenlight/2461331/Daxxify™ (DaxibotulinumtoxinA-lanm) from Revance is FDA approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults. Daxxify is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum
- Allergan Aesthetics Hits Milestone: 100 Million Syringes of JUVÉDERM Shippedhttps://practicaldermatology.com/news/allergan-aesthetics-hits-milestone-100-million-syringes-of-juvederm-shipped/2461330/Drumroll, please…Allergan Aesthetics, an AbbVie company has produced and shipped 100 million syringes of JUVÉDERM products globally. Since its launch in 2000, the JUVÉDERM Collection of Fillers has grown to where its products are now avail
- Boehringer Ingelheim's Spevigo Is first Treatment FDA-Approved for GPPhttps://practicaldermatology.com/news/boehringer-ingelheims-spevigo-is-first-treatment-fda-approved-for-gpp/2461327/FDA has approved Spevigo (spesolimab) from Boehringer Ingelheim as the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spevigo is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a key part of a signali
- FDA Clears LASEROPTEK's HELIOS IV-785 for Aesthetic and Medical Dermatology Usehttps://practicaldermatology.com/news/fda-clears-laseropteks-helios-iv-785-for-aesthetic-and-medical-dermatology-use/2461326/The U.S. Food and Drug Administration has granted 510(k) clearance to LASEROPTEK Co., Ltd.’s HELIOS IV-785 laser system for aesthetic and medical dermatology applications. HELIOS IV-785's novel and synergistic combination of 785nm picosecond photoacoustic effect and 1064 &
- Psoriasis, Other Autoimmune Diseases Up Risk for CVDhttps://practicaldermatology.com/news/psoriasis-other-autoimmune-diseases-up-risk-for-cvd/2461323/Earlier research has suggested associations between some autoimmune disorders and a higher risk of cardiovascular disease, and now, a new study shows that nineteen of the most common autoimmune disorders seem to increase risk for developing heart disease. Patients with autoim
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous BCChttps://practicaldermatology.com/news/sirnaomics-achieves-100-complete-response-in-phase-ii-clinical-trial-of-stp705-for-treatment-of-cutaneous-bcc/2461319/Patients receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response, with no safety signals, Sirnaomics reports. STP705 is a siRNA (small inte
- Tecovirimat Safe and Effective for Treating Skin Lesions of Monkeypoxhttps://practicaldermatology.com/news/tecovirimat-safe-and-effective-for-treating-skin-lesions-of-monkeypox/2461318/The antiviral tecovirimat appears to be safe and effective for the treatment of monkeypox symptoms and skin lesions, according to a research letter published in JAMA. The study is one of the ea
- Study: Colorescience Total Eye Firm & Repair Cream Improves Appearance of Overall Periorbital Areahttps://practicaldermatology.com/news/study-colorescience-total-eye-firm-repair-cream-improves-appearance-of-overall-periorbital-area/2461316/Colorescience Total Eye Firm & Repair Cream improves periorbital wrinkles, dryness, laxity and dark circles, according to a study in the Journal of Cosmetic Dermatology. Results of the clinical study
- Cutera Recognized by 50/50 Women on Boards for Gender-Balanced Board of Directorshttps://practicaldermatology.com/news/cutera-recognized-by-5050-women-on-boards-for-gender-balanced-board-of-directors/2461315/The 50/50 Women on Boards recognized Cutera for having a gender-balanced board. With four women directors, holding 50 percent of its corporate board seats, Cutera, Inc. is one of only 8 percent (just 241) of Russell 3000 companies with a gender-balanced board. &ldq